🎉 Datroway (Datopotamab Deruxtecan) Approved in the US for Metastatic HR-Positive, HER2-Negative Breast Cancer 🎗️
A major milestone in breast cancer treatment! The FDA has approved Datroway (Dato-DXd) for patients with previously treated metastatic HR-positive, HER2-negative breast cancer, offering a new alternative to conventional chemotherapy.
🔬 Why This Matters:
✔️ 37% reduction in the risk of disease progression or death (TROPION-Breast01 trial)
✔️ A novel TROP2-directed ADC, targeting cancer cells more precisely
✔️ Part of AstraZeneca’s ambitious goal to deliver 20 new medicines by 2030
💬 Dr. Aditya Bardia (UCLA): “This approval marks a major therapeutic milestone, providing a new treatment option for patients facing disease progression.”
💬 AstraZeneca & Daiichi Sankyo: “Datroway is changing the paradigm—pushing ADCs beyond traditional chemotherapy in multiple cancers.”
💡 What’s Next? Regulatory reviews are ongoing in EU, China, and other regions, signaling a global impact.
🚀 A new era in metastatic breast cancer treatment is here. Let’s keep pushing boundaries! 💪
